Shares of Aeglea Biotherapeutics Inc. fell 2% late Thursday after the company announced that Chief Executive David G. Lowe has resigned, effective immediately. Board member Anthony Quinn has been appointed to serve as interim chief executive officer while the company conducts a comprehensive search for a permanent chief executive officer, the company said in a statement. Shares ended the regular session up 2%.
Copyright © 2017 MarketWatch, Inc.
Continue Reading Below